Search

Displaying results 4891 - 4900 of 10000 in total
  1. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    Reviparin has a molecular weight of 3.9 kDa.[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

    Products: CLIVARIN 5726 IE A XA/ML, CLIVARODI 17178 A XA/ML
  2. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. … The expression of the endogenous AX200 protein in the brain is increased after brain damage.

  3. Drug

    Bevasiranib

    go.drugbank.com/drugs/DB06642
    Investigational

    Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is a small molecule drug. Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients). … Maytansine has a monoisotopic molecular weight of 691.29 Da.

  5. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  6. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  7. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  8. Drug

    Dabigatran

    go.drugbank.com/drugs/DB14726
    ApprovedInvestigational

    Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

    Categories: Factor Xa Inhibitors, Direct factor Xa inhibitors
  9. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.